Elevation Oncology Inc (ELEV) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Elevation Oncology inc   (NASDAQ: ELEV)

Elevation Oncology Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Elevation Oncology Inc in the first quarter 2025?
Elevation Oncology Inc recorded a cumulative net loss of $-48 million during 12 months ending in the first quarter 2025, resulting in a negative return on equity (ROE) of -74.68%.

Within the Biotechnology & Pharmaceuticals industry 72 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2024 from 2611 to 3213.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Equity Change -38.36 % 9.52 % 11.12 % 12.1 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -48 -44 -42 -40 -39
Return On Equity (TTM) -74.68 % -62.19 % -59.73 % -57.97 % -59.35 %
ELEV's Total Ranking # 3213 # 2611 # 2668 # 1272 # 706
Equity (TTM) in Millions 47 60 69 81 76
Seq. Equity Change -22.14 % -13.45 % -14.29 % 6.73 % 38.33 %
Seq. Net Income Change - - - - -

Back to ELEV Management Effectiveness >> ELEV's 5 Years Annual ROE >> Compare ELEV ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 73
Sector # 505
Overall # 3213

Return On Equity Statistics
High Average Low
-12.13 %
-77.21 %
-153.17 %
(Mar 31 2022)   (Jun 30 2023)





ELEV Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 60 55 49 141 0
Y / Y Equity Change 9.52 % 11.78 % -65.15 % - -
Net Income in Millions -44 -46 -95 -32 0
Y / Y Net Income Change - - - - -
Return On Equity -74.11 % -83.39 % -193.91 % -22.77 % -

Back to ELEV Management Effectiveness >> ELEV's 5 Years Annual ROE >> Compare ELEV ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ELEV's' Return on Equity at Yahoo Finance
ELEV's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ELEV's Competitors
Subscribers only: Roe for Elevation Oncology Inc 's Suppliers
Subscribers only: Return On Equity for ELEV's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE

Date modified: 2026-10-05T11:03:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.